Palbociclib

About

Therapy type: Targeted therapy

Therapy strategy: CDK4/6 inhibition

Mappings

NCI Thesaurus: Palbociclib (coding:ncit:C49176)

RxNorm: palbociclib (coding:rxcui:1601374, coding:omop:45892075)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
EMA (2) FDA (4) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant, Palbociclib
EMA (2) FDA (4) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib
EMA (2) FDA (4) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib
EMA (1) FDA (2) ER positive, HER2-negative Invasive Breast Carcinoma Letrozole, Palbociclib
EMA (1) FDA (2) HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Palbociclib
EMA (1) FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Palbociclib
EMA (1) FDA (2) ER positive, HER2-negative, PIK3CA oncogenic variants Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib
EMA (1) FDA (2) HER2-negative, PIK3CA oncogenic variants, PR positive Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib
EMA (1) FDA (2) ER positive, HER2-negative, PIK3CA oncogenic variants, PR positive Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib
EMA (1) ER positive, ESR1 activating variants, HER2-negative Invasive Breast Carcinoma Camizestrant, Palbociclib